European Perspectives Videos
February 2014—In this interview, Felicia M. Knaul, of the Harvard Global Equity Initiative, and Mark Lawler, of Queens University Belfast, explore the deep “cancer divide” that exists between high-income countries and low-and middle income countries (LMICs) and the challenges involved in closing it. They identify a change in health care strategy, a unity of purpose, and effective partnerships among all stakeholders as requirements in addressing the cancer divide and conclude that introducing a series of effective, low-cost interventions in cancer care and control must be a priority for all health systems in LMICs.
August 2013—In this interview, Dr. Partridge discusses the needs of a particularly vulnerable cancer survivor population, young women living with breast cancer, and outlines the unique challenges that they face following successful treatment for their malignancy. The article also reviews the achievements of Dana Farber’s Program for Young Women with Breast Cancer over the last seven years, highlighting how the solutions applied to the 2,000+ participants may potentially be exported and adapted for application in other countries and regions.
July 2013—This roundtable invites US and European oncology leaders to discuss the prospect of stratified medicine within a global clinical trial network. They argue cogently for a more modern and personalized approach of clinical trials, harnessing the promise of discovery biology and translational medicine within an innovative global cooperative cancer clinical trial culture that delivers true transformational benefit to the cancer patient. “We should be competing against our common enemy, cancer, rather than against each other.”
Personalized Medicine: Does the Molecular Suit Fit?
Edison Liu and Patrick Johnston
June 2013—This roundtable highlights the increasing importance of genetic context in our treatment algorithms for solid tumors, as exemplified by the role of RAS mutational testing in concert with therapeutic targeting of the epidermal growth factor receptor in colorectal cancer. Liu and Johnston emphasize the need for coordinated therapeutic and diagnostic innovation pipelines, with new therapies and their diagnostics linked at the level of development, approval, clinical application and reimbursement.
May 2013—As an increasing percentage of younger women are now surviving breast cancer, a growing number of them rightly place reproductive health high up on their agenda. This was one of the themes that was discussed at the European School of Oncology (ESO) Breast Cancer in Young Women Conference in Dublin, November 2012. European Perspectives addresses this important topic with two experts in this area, Prof. Olivia Pagani, Institute of Oncology of Southern Switzerland (IOSI) and Prof. Dror Meirow, Sheba Medical Center, Ramat Gan, Israel.
April 2013—In this interview, the second in a series of conversations with global experts on fertility preservation in young women with breast cancer, Dror Meirow discusses the available options for fertility preservation. A number of approaches have been employed including embryo and oocyte cryopreservation, ovarian tissue cryopreservation, and ovarian suppression with gonadotropin-releasing hormone agonists. Storing ovarian tissue with a view to future re-implantation is an approach that Meirow pioneered in 2005 and in the interview he outlines the results that have been achieved.
Lung Cancer: From Prevention to Cure
Thierry Le Chevalier
March 2013—In this interview, Thierry Le Chevalier, recently elected Founding President of the Institut d'Oncologie Thoracique and Co-Editor of European Perspectives, discusses the significant challenges that health care professionals face in treating lung cancer and highlights how a more complete understanding of the biology of lung cancer is shaping new therapeutic algorithms that may yield significant benefit. Results from a number of recent clinical trials, targeting specific molecular abnormalities in Non-Small Cell Lung Cancer have the potential to become new standards of care in this deadly disease.
February 2013—Interview with Prof. Maureen Trudeau, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada.
ESO and The Oncologist: Announcing a New Strategic Alliance in Cancer Education
Alberto Costa and Franco Cavalli
January 2013—As part of the The Oncologist’s continuing engagement with the European oncology community and recognising the role that the European School of Oncology (ESO) has played in cancer education in Europe, The Oncologist is pleased to announce a new, collaborative agreement with ESO.
January 2013—Interview with Prof. Bob Pinedo, Co-Editor The Oncologist, European Edition at the World Oncology Forum in Lugano Switzerland, celebrating 30 years of the European School of Oncology
November 2012—Dr William Hait, Global Head Janssen Research and Development, shares his vision on the need for approaches that empower functional partnerships between academia and industry to deliver transformational advances for cancer patients. This new approach requires a clear understanding of the medical need, coupled with the most compelling science to deliver meaningful innovations to patients in a rapid fashion.
August 2012—In this interview, Dr. O’Carroll highlights the significant contribution that a co-ordinated research funding and policy strategy has made to European science over the last 20 years, how the scientific community has engaged successfully with the Seventh Framework Programme for Research and Technological Development (FP7) and what this engagement has meant in particular to the cancer researcher, the cancer physician and, most importantly, the cancer patient.
June 2012—The European Organization for Research and Treatment of Cancer (EORTC) is a key enabler of translational and clinical research in Europe through its overarching support of the multidisciplinary transnational efforts of basic scientists and clinicians. As it celebrates its 50th Anniversary, this interview and accompanying article highlight a number of the successes of EORTC and identify the key challenges that it faces in its pioneering role in cancer research and cancer treatment in Europe.
Future Frontiers and Challenges in Cancer Medicine
Patrick G. Johnston
May 2012—Transformational changes in cancer treatment must occur in this era of molecular stratification and targeted therapy. An increased understanding of cancer biology, coupled with the implementation of precise ‘omics technologies, has revealed that cancer must be considered as a heterogeneous disease. Therefore our historical “one size fits all” therapeutic approach is no longer valid and new treatment algorithms must be developed and tested rigorously in selected patient populations.
European Perspectives: A Dialogue with the European Oncology Community
April 2012—As part of our commitment to the European cancer community, this issue of The Oncologist European Edition introduces a new initiative entitled European Perspectives. Under the stewardship of Section Co-Editors, Thierry Le Chevalier (Paris, France) and Pierfranco Conte (Modena, Italy), European Perspectives will be a regular monthly feature and will provide expert up-to-date information on topics that are most relevant to the European oncology community, through a combination of print articles and online material.
The Oncologist European Edition proudly introduces European Perspectives
Patrick G. Johnston
April 2012—As a catalyst for debate and opinion leader in the oncology community, European Perspectives provides expert up-to-date information in response to pressing European oncology issues and current concerns, highlighting breakthroughs in cancer care and cancer research. Using this multimedia platform, European Perspectives provides balanced commentary on relevant policy and funding developments, confronting significant issues that are of relevance to the cancer community and allowing for a vigorous two-way pan-European dialogue.